The Enterprisers

  1. How Can Drug Developers Work Together With The FDA To Maximize The Value Of A Clinical Trial Protocol? 8/1/2023

    See the answer from Mitchell Katz, PhD, SVP, global clinical operations, at Kyowa Kirin.

  2. Why Counterfeit And Substandard Antibiotics Matter To The Pharma Industry 8/1/2023

    Due to a lack of regulation and enforcement in such regions, as well as a lack of access to quality healthcare, the antibiotic “gray market” is fertile ground for exploitation.

  3. Why ERGs Are Critical To A Company's Future Success 8/1/2023

    There’s a common misconception that employee resource groups (ERGs) are purely social clubs — a view that completely misses the potential for these groups to drive business innovation, strategy, and talent development.

  4. State Scrutiny Of Drug Pricing Intensifies With Rise Of PDABs 8/1/2023

    More than five years after state price transparency laws began spreading throughout the country, states have opened up a new front in their battle against what they deem to be excessively high prescription drug prices through the establishment of prescription drug affordability boards (PDABs).

  5. Understanding Data Collection And Management In DCTs 8/1/2023

    For decentralized clinical trials (DCTs), it is important to specify the risks up front and determine if — and how — this approach can be applied to each protocol. Further, from a data collection and management standpoint, there is plenty to consider in terms of data flow management through multiple sources and systems.

  6. Cell & Gene Therapies Manufacturing Market Outlook 8/1/2023

    In ISR’s Cell & Gene Therapies Manufacturing Market Outlook (2nd Edition) research participants were asked to select the cell and gene manufacturing activities their company would outsource to CDMOs in the next 18 months and in five years.

  7. In These Times Of Increasingly Unpredictable And Lurching Change, What Skills Will Separate Out Next-Gen CEOs? 8/1/2023

    See the answer from Fred Hassan, the managing director at Warburg Pincus.

  8. Adjusting Industry Expectations of Investigators: Why It Matters 8/1/2023

    Considering less than 3% of physicians engage in clinical research, with a high percentage leaving after just one trial, what can be done to get more investigators interested in participating — and staying involved?

  9. How To Be A Leader Employees Don't Leave 8/1/2023

    Being a leader who people want to stick with requires you to create a compelling vision of where you are going and taking your team — and you need to be able to communicate all of that in the same compelling manner.

  10. Novo Nordisk Returns To Growth, With Growing Pains 8/1/2023

    Novo Nordisk’s return to growth is largely due to an explosion of demand for its anti-obesity products. However, challenges with supply and insurance coverage persist.